The primary goal of the PRAISE study is to develop a diagnostic algorithm that allows the prediction of acute coronary syndrome in stroke patients with elevated levels of cardiac troponin.
Inclusion Criteria: * diagnosis of ischemic stroke based on clinical and imaging information (CT or MRI) * diagnosis of transient ischemic attack if the initial focal neurological deficit has been examined by a neurologist and if the ABCD2-score is ≥ 4 * Elevation of high-sensitive cardiac troponins according to the rule-in/rule-out algorithm of the 2015 ESC guidelines for NSTE-ACS, i.e. highly abnormal troponin at 0 hours (\> 52ng/l if hs-cTnT, Elecsys-Assay, or \> 52ng/l, if hs-cTnI; Architect-Assay, or \> 107 ng/l, if hs-cTnI. Dimension Vista Assay) or dynamic change \> 20% of the initial value at re-test after 3 hours with at least one value above the 99th percentile of a healthy reference population * ability to give informed consent * onset of symptoms \< 72 hours prior to hospital admission Exclusion Criteria: * renal insufficiency (GFR \< 30 ml/min/m²) * contraindications for coronary angiography (e.g. manifest hyperthyroidism, allergy to contrast agent) * lesion size \> 100 ml (either on Diffusion Weighted Imaging on cMRI or on CT if CT is performed \> 24 hours after onset) or ASPECTS score \< 7 (on CT if CT is performed \< 24 hours after onset) * Premorbid degree of dependence (mRS \> 3) * pregnancy or breast-feeding * limited life expectancy \< 1 year * consent to participate in the study given \> 72 hours after hospital admission